FY2025 EPS Estimates for ELDN Lifted by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($0.73) per share for the year, up from their prior forecast of ($1.23). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share.

ELDN has been the topic of a number of other research reports. Wall Street Zen raised Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday. Guggenheim started coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a "buy" rating and a $9.00 price objective on the stock.

Eledon Pharmaceuticals Stock Performance

Eledon Pharmaceuticals stock traded up $0.03 on Monday, reaching $3.05. The company's stock had a trading volume of 175,430 shares, compared to its average volume of 273,037. The company has a market cap of $182.64 million, a price-to-earnings ratio of -1.52 and a beta of 0.08. The business's fifty day moving average price is $3.12 and its 200 day moving average price is $3.88. Eledon Pharmaceuticals has a twelve month low of $2.30 and a twelve month high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.20.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in shares of Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock valued at $33,000 after acquiring an additional 6,412 shares during the period. CW Advisors LLC bought a new stake in Eledon Pharmaceuticals in the first quarter valued at about $34,000. Y Intercept Hong Kong Ltd bought a new stake in Eledon Pharmaceuticals in the first quarter valued at about $41,000. Alpine Global Management LLC bought a new stake in Eledon Pharmaceuticals in the fourth quarter valued at about $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in Eledon Pharmaceuticals in the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).